Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a biotech firm focused on a buccal film drug delivery system that administers a psilocybin formulation aimed at treating anorexia nervosa—a condition with no currently approved pharmacological therapies. Pre-clinical safety studies have shown strong safety and tolerability at high doses, supporting continued development of the program. In parallel, the company is pursuing a “dual-path” strategy that includes creating a Digital Asset Treasury intended to provide non-dilutive capital for future research initiatives. For the fiscal year ending 30 April 2025, Shortwave generated £45,700 in revenue, a 19 % decline year over year, and recorded an operating loss of £269,811, an improvement from the £846,338 loss reported in 2024. Year-end cash stood at just £2,912, and auditors flagged material uncertainty about the company’s ability to continue as a going concern without additional financing. The recent fundraises are therefore critical to sustaining operations and advancing its lead program. The firm also issued shares to service providers in lieu of cash fees to conserve capital.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025